Facial Lipoatrophy: Why Some Faces Lose Their Fat for Reasons That Have Nothing to Do With Age, What HIV-Associated Wasting and Parry-Romberg Syndrome Require Before Anyone Reaches for a Syringe, and How Fillers, Fat, and Flaps Rebuild Volume

A patient sits down in a consultation room and points at their cheeks. The hollows under the cheekbones are deep, the temples have sunk, and the skin over the front of the face looks draped rather than supported. They are forty-five, not seventy. They have not lost much weight. They want filler, and they want it this week.

Most of the time, a face like that is a story about genetics, leanness, sun, or a recent change in weight, and the treatment conversation follows a familiar track. But a meaningful minority of patients with that complaint have something else going on: a loss of facial fat caused by a disease, a medication, or an earlier injection. The medical term is facial lipoatrophy, meaning wasting of the fat compartments of the face, and it changes the order in which things should happen. A filler placed into a face that is still actively losing fat will be outpaced. A fat graft harvested from a patient who has lost most of their fat everywhere may not be available at all. And a one-sided hollow in a teenager may be the visible edge of an autoimmune condition that belongs with a rheumatologist before it belongs with an injector.

This piece is about those patients. It covers the main causes of true facial lipoatrophy, how each is recognized, what the FDA has approved specifically for it, and how the reconstruction ladder, from hyaluronic acid to microvascular tissue transfer, is matched to the cause and the severity. The general story of volume loss with age and weight loss is told in the piece on Ozempic face and facial volume loss; this one starts where that one stops.

What facial lipoatrophy is, and how it differs from ordinary volume loss

The short answer: facial lipoatrophy is a loss of fat from the facial compartments caused by a specific process, such as a medication, an autoimmune disease, or a local injection, rather than by aging or overall weight loss, and the clues are a pattern of loss out of proportion to the patient's age and body weight, a one-sided or patchy distribution, or a clear link in time to a drug or a disease.

The face holds its fat in distinct compartments: superficial pads just under the skin and deeper pads that sit against bone and muscle. With age, some of those compartments shrink and others descend, which is the hollowing and sagging that most facial rejuvenation addresses. Rapid weight loss accelerates the same pattern. Neither process requires a diagnosis. Both tend to be roughly symmetric, gradual, and proportionate to what is happening in the rest of the body.

Lipoatrophy looks different in a few characteristic ways. The loss can be dramatic in a patient who is otherwise of normal weight. It can concentrate in particular compartments, most often the buccal and submalar region below the cheekbone, the temples, and the area in front of the ear, so that the cheekbones and the zygomatic arch stand out sharply while the lower face looks sunken. It can be confined to one side. And it often has a history attached: a medication started a few years earlier, a series of injections, a rash or a hardened band of skin that came before the hollowing.

The distinction matters because it changes three practical things. First, whether the loss is still active, since filling a moving target is expensive and frustrating. Second, what tissue the patient has available to donate, since some causes of facial fat loss also strip fat from the arms, legs, and buttocks. Third, whether there is a doctor other than a cosmetic one who should be involved, because several of the causes are systemic conditions with implications well beyond the face.

A careful surgeon or injector will take a history before planning any volume treatment and will ask a handful of questions that sound unrelated to aesthetics: when the change started, whether it is getting worse, whether it is on one side or both, what medications the patient takes or has taken, whether there has been any skin hardening, discoloration, or hair loss over the area, and whether fat has been lost or gained elsewhere on the body. The answers sort most patients quickly into one of the groups below.

HIV-associated facial wasting: the drugs that caused it, why it lingers, and what was approved to treat it

The short answer: the facial wasting seen in many people living with HIV was strongly linked to older antiretroviral drugs, especially the thymidine analogues stavudine and zidovudine, and although modern regimens rarely cause it, many long-term survivors still carry the hollowing; it was the first indication for which the FDA approved the biostimulatory fillers poly-L-lactic acid and calcium hydroxylapatite.

In the late 1990s and early 2000s, as combination antiretroviral therapy turned HIV from a fatal illness into a chronic one, clinicians began describing a syndrome of fat redistribution in their patients. Fat disappeared from the face, arms, legs, and buttocks, while in some patients it accumulated around the abdominal organs, at the back of the neck, and in the breasts. The facial component was the most visible and, for many patients, the most distressing, because sunken cheeks and temples had become associated in the public mind with advanced illness. Patients described the face as a disclosure they had not chosen.

Research over the following decade pointed most firmly at a class of drugs called nucleoside reverse transcriptase inhibitors, and in particular at the thymidine analogues stavudine and zidovudine, which can damage the mitochondria of fat cells. Studies published in journals such as AIDS and the Journal of Acquired Immune Deficiency Syndromes found that switching patients away from those drugs generally halted further loss and allowed slow, partial recovery of limb fat, but that the face often recovered little. Current regimens built around drugs such as integrase inhibitors and tenofovir are much less associated with lipoatrophy (some are associated with weight gain instead), and stavudine has been largely abandoned worldwide. The result is a population of long-term survivors, many now in their fifties and sixties, whose facial wasting was caused decades ago and has never reversed.

That history explains the regulatory record. In 2004, the FDA approved injectable poly-L-lactic acid, sold as Sculptra, specifically for restoring and correcting the signs of facial fat loss in people with HIV. In 2006, it approved calcium hydroxylapatite, sold as Radiesse, for the same indication. Both are biostimulatory fillers: rather than simply occupying space, they provoke the body to lay down new collagen around the injected particles over a period of months. The cosmetic approvals for wrinkles in the general population came afterward. The mechanics and the slow timeline of poly-L-lactic acid are covered in the piece on the Sculptra collagen-building timeline, and the broader comparison with hyaluronic acid is set out in the piece on biostimulatory fillers versus hyaluronic acid.

Coverage is the other piece of the history. In 2010, the Centers for Medicare and Medicaid Services issued a national coverage determination allowing Medicare coverage of FDA-approved dermal injections for facial lipodystrophy in people with HIV, under specific conditions that include documentation that the facial changes have contributed to depression. Private insurers vary widely, and many treat the injections as cosmetic. The documentation habits that improve any appeal, from photographs to letters from the treating physician, are described in the piece on insurance and medical necessity.

Treatment planning for HIV-associated wasting has a few specific considerations. The injector should know the patient's current regimen and whether it has been stable, because a face that is still losing fat on an older drug will keep losing it. The amount of product required is often far larger than in cosmetic practice: a severely wasted midface can take several vials per side, over several sessions, which is why the biostimulators, with their longer duration, became the default rather than hyaluronic acid. And the patient's overall fat stores matter for any surgical option, a point that returns below.

"

A filler cannot outrun the process that is removing the fat. The first question in a hollow face that does not match the patient's age is not which product to use; it is whether the loss has stopped.

"

Parry-Romberg syndrome and the other causes: one-sided atrophy, acquired lipodystrophy, and injection dents

The short answer: Parry-Romberg syndrome, also called progressive hemifacial atrophy, slowly wastes the skin, fat, and sometimes the muscle and bone on one side of the face, usually beginning in childhood or adolescence and then stabilizing after years; other causes include the rare acquired lipodystrophies, lupus panniculitis, and the localized fat loss that can follow a corticosteroid injection.

Parry-Romberg syndrome is uncommon, but it is the condition most likely to send a young patient to a plastic surgeon with a face that looks lopsided. The atrophy typically begins in the first two decades of life on one side of the face, often in the cheek or the forehead, and progresses slowly for a period that the literature usually describes as somewhere between two and ten years or more before it enters a stable, burned-out phase. It can involve the skin, the fat beneath it, the muscles, and in more severe or earlier-onset cases the underlying bone, so the cheek flattens, the eye can sink back into the orbit, and the jaw and chin on the affected side may be smaller. Changes in skin color, loss of hair in the eyebrow or scalp on that side, and in some patients neurological symptoms such as headaches or seizures can accompany it.

The condition overlaps closely with a form of localized scleroderma called linear morphea en coup de sabre, a hardened, indented band that typically runs vertically on the forehead and scalp, and many specialists now regard the two as points on the same spectrum. That overlap is why a patient with suspected Parry-Romberg syndrome should be evaluated by a dermatologist or rheumatologist, and often a neurologist and eye specialist, before any reconstruction is planned. When the disease is active, it is commonly treated with immunosuppressive medication, most often methotrexate, sometimes with corticosteroids, with the goal of halting progression. Reconstruction is traditionally deferred until the disease has been stable for a period, often cited as at least a year or two, although some centers now report fat grafting during the active phase without apparent harm, and that question remains open in the literature. The broader principles of operating on patients with autoimmune conditions are covered in the piece on cosmetic surgery with autoimmune disease, and the approach to asymmetry in general in the piece on facial and breast asymmetry.

The acquired lipodystrophies are rarer still. Acquired partial lipodystrophy, sometimes called Barraquer-Simons syndrome, typically begins in childhood or early adulthood with fat loss in the face that spreads downward to the neck, arms, and trunk, while the hips and legs are spared or gain fat. It is more common in women, and it is associated with an abnormal complement protein in the blood and, in some patients, with a form of kidney disease. Generalized lipodystrophies, whether inherited or acquired, cause fat loss across the whole body and come with serious metabolic problems, including severe insulin resistance and high triglycerides, which are managed by endocrinologists. A cosmetic surgeon is unlikely to make these diagnoses, but should recognize when a patient's pattern of fat loss and medical history do not fit ordinary aging and should send them for a workup before treating the face.

Two more causes are worth knowing because they are relatively common. Lupus panniculitis, also called lupus profundus, is an inflammation of the fat in some patients with lupus that can leave firm nodules that later resolve into deep dents, often on the cheeks, upper arms, or buttocks. And a corticosteroid injection, given for a keloid, a cyst, acne, or a joint, can cause a localized depression of the fat and thinning of the skin at the injection site, sometimes with visible blood vessels and lightened color. Steroid-induced atrophy often improves on its own over months to a year or more, which is a reason to wait before filling it. The keloid and cyst injections that most often cause it are discussed in the piece on cyst and lipoma removal.

The reconstruction ladder: hyaluronic acid, biostimulators, fat grafting, implants, and transferred tissue

The short answer: mild lipoatrophy is usually treated with injectable fillers, moderate to severe cases with biostimulatory fillers or serial fat grafting, and the most severe defects, particularly in Parry-Romberg syndrome with bone or deep tissue loss, with dermal-fat grafts, implants, or microvascular transfer of tissue from elsewhere in the body, with the choice shaped by how much donor fat the patient has.

Hyaluronic acid fillers are the entry point. They are reversible, which matters in a face whose underlying condition may still change, and they work well for small, well-defined hollows, such as a steroid dent or a mild temple deficit. Their limitation is volume and longevity: a severely wasted face may need a quantity of product that becomes expensive to maintain every year or so. The considerations specific to the temples, where much lipoatrophy concentrates, are discussed in the piece on filler for hollow temples, and the safety issues that scale with volume and injection depth, including vascular occlusion and delayed nodules, are set out in the piece on filler vascular occlusion risk and the piece on delayed filler nodules.

Biostimulatory fillers carry most of the load in moderate HIV-associated wasting, for the reasons given above, typically delivered in a series of sessions spaced weeks apart with results that build over months and can last two years or longer. Permanent fillers occupy a contested corner of this field. Microdroplet injections of medical-grade liquid silicone were used off label by a small number of physicians for HIV lipoatrophy, and polyacrylamide gels have been used for the same purpose outside the United States, but permanence cuts both ways: a complication from a permanent product can be permanent too. The history and the risks are reviewed in the piece on illegal silicone injections and biopolymers, which separates the narrow medical use from the black-market injections that have caused so much harm.

Fat grafting is the surgical workhorse, and it is where the cause of the lipoatrophy matters most. Fat is harvested by liposuction, processed, and injected in small amounts into the depleted compartments; the technique is described in the piece on fat transfer to the face, with the biology of why some of it survives and some does not in the piece on fat graft survival. Parry-Romberg patients usually have normal fat elsewhere and are often good candidates, though the scarred, thinned tissue on the affected side can be a poor bed, and multiple sessions are the rule rather than the exception. Patients with HIV-associated or acquired lipodystrophy may have very little fat left in the usual donor areas. Surgeons have reported using the fat that some of these patients accumulate instead, including the fat pad at the back of the neck described in the piece on buffalo hump liposuction, with the caveat that fat which grew because of a metabolic disturbance may not behave the same way once moved. Finer, processed fat, discussed in the piece on nanofat and microfat, is sometimes used under thinned skin to improve its quality, but it adds little volume.

For defects too large or too deep for injections, the options become structural. A dermal-fat graft, a solid block of skin's deeper layer and the fat attached to it, can fill a well-defined depression in one stage, as explained in the piece on dermal-fat grafts versus fat transfer. Where bone is deficient, as in some Parry-Romberg patients, cheek, jaw, or chin implants or bone grafts can restore the skeletal frame that soft tissue drapes over; the implant options are covered in the piece on facial implants for the cheek and jaw. And for the most severe one-sided atrophy, reconstructive surgeons can transfer a flap of fat and deep tissue, often from the back near the shoulder blade or from the thigh, with its own artery and vein, and reconnect those vessels to vessels in the face under a microscope. Microvascular transfer brings a large, living volume in one operation, at the cost of a longer surgery, a donor-site scar, and frequent secondary procedures to thin or adjust the flap, a trade similar to the one described for muscle transfer in the piece on synkinesis and facial reanimation.

Who should treat it, how long results last, and the questions that protect the patient

The short answer: mild lipoatrophy can be treated by an experienced injector working under appropriate medical supervision, but disease-related or severe cases belong with a board-certified plastic surgeon or dermatologist who treats reconstructive volume loss and coordinates with the patient's other doctors, and every treatment, from filler to transferred tissue, should be planned with the expectation of maintenance or revision.

The volumes involved in treating real lipoatrophy change the risk calculation. Injecting several vials into the midface and temples, often deep against bone, requires anatomical knowledge and the ability to manage a vascular complication on the spot. The questions to ask about who is holding the syringe, and who supervises them, are set out in the piece on who is injecting you. Fat grafting and the structural options are surgical, and for Parry-Romberg syndrome in particular, the patients who do well are generally those treated by teams that see the condition repeatedly, with input from dermatology or rheumatology on disease activity and, in children, careful thought about how the face will continue to grow.

Durability is uneven across the ladder. Hyaluronic acid typically lasts months to a little over a year in the face. Biostimulators often last two years or more, though the collagen they induce gradually remodels. Fat that survives the first few months is generally considered long-lasting, but it changes with the patient's weight, and in a person whose underlying lipodystrophy has not stabilized, it can be lost along with the native fat. Even microvascular flaps change shape over years and frequently need refinement. A realistic overview of how long different procedures hold up, and why the honest answer is usually a range, is given in the piece on how long plastic surgery results last.

The psychological weight of these conditions deserves direct acknowledgment. People with HIV-associated wasting have described the facial changes as a source of stigma and involuntary disclosure, and studies have linked lipoatrophy to depression and to some patients stopping or avoiding treatment. Patients with Parry-Romberg syndrome often grew up with a visibly asymmetric face. Treatment can make a real difference to how they feel in public. It should also be planned with honesty about the ceiling: restoring volume to a severely wasted face is achievable, and making it indistinguishable from a face that never lost its fat often is not. The recovery and expectations side of that conversation is discussed in the piece on emotional recovery after plastic surgery.

The honest summary

Most hollow faces are the product of age, genetics, and weight change, and are treated as such. Facial lipoatrophy is different: a loss of facial fat driven by a specific cause, most notably the older HIV medicines stavudine and zidovudine, the slow one-sided atrophy of Parry-Romberg syndrome, the rare acquired lipodystrophies, lupus panniculitis, and corticosteroid injections. The tools for rebuilding the face are the familiar ones, from hyaluronic acid and the biostimulators the FDA first approved for HIV-associated wasting, through fat grafting and dermal-fat grafts, to implants and microvascular tissue transfer for the most severe defects.

What changes is the sequence. The cause should be identified, and where possible stopped, before volume is added. One-sided wasting, a history of skin hardening, or fat loss elsewhere on the body calls for a specialist evaluation first. Donor fat may be scarce, so the surgical plan depends on what the patient's body has left to give. And the treatment should be priced and planned as a course rather than a single visit. The practitioner worth trusting with a face like this is the one who asks why it lost its fat before deciding how to replace it.